Health Law & Business News

Medicare Advisers to Weigh Novel Cancer Treatment Coverage

Aug. 8, 2018, 8:14 PM

Medicare advisers this month will consider coverage of a novel and expensive cancer–fighting therapy and the best ways to assess patient reported outcomes in studies of the therapy.

The Medicare Evidence Development & Coverage Advisory Committee Aug. 22 will take up the topic of chimeric antigen receptor T-cell immunotherapy. Known as CAR-T, the new treatment is for patients with advanced cancer. The Food and Drug Administration so far has approved two CAR-T therapies for adults: Novartis Pharmaceuticals’ Kymriah, and Gilead Sciences’ Yescarta, each costing $373,000 for the one-time treatment.

As part of its analysis of CAR-T, committee members will review...

To read the full article log in. To learn more about a subscription click here.